Transdermal nicotine as maintenance therapy for ulcerative colitis

Area of Science:

• Gastroenterology
• Pharmacology

Background:

• Ulcerative colitis (UC) is a chronic inflammatory bowel disease predominantly affecting non-smokers.
• Previous research indicated nicotine's potential benefit in active UC treatment.

Purpose of the Study:

• To evaluate the efficacy of transdermal nicotine for maintaining remission in ulcerative colitis patients.
• To assess the safety and tolerability of transdermal nicotine in UC remission maintenance.

Main Methods:

• A randomized, double-blind, placebo-controlled study involving 80 ulcerative colitis patients in remission.
• Patients received either transdermal nicotine patches or placebo for six months, with mesalamine treatment discontinued after nicotine titration.
• Clinical, sigmoidoscopic, and histologic assessments were performed, alongside monitoring of side effects and nicotine/cotinine levels.

Main Results:

• No significant difference in relapse rates was observed between the nicotine and placebo groups.
• Higher rates of premature withdrawal occurred in the nicotine group, attributed to relapse and side effects (nausea, lightheadedness, itching).
• Serum nicotine and cotinine levels in the nicotine group were lower than anticipated, suggesting potential compliance issues.

Conclusions:

• Transdermal nicotine monotherapy is ineffective for maintaining ulcerative colitis remission.
• Nicotine patches were associated with increased side effects and withdrawals compared to placebo, limiting their therapeutic utility in this context.